Pooled analyses of the roxadustat global Phase III
This announcement contains inside information 10 May 2019 07:00 BST Pooled analyses of the roxadustat global Phase IIIprogramme confirmed cardiovascular safety Cardiovascular safety endpoints evaluated across CKD patientsnot on dialysis, on incident dialysis and on stable dialysis Better outcome vs. epoetin alfa in incident-dialysis patientsand comparable to placebo in patients not on dialysis AstraZeneca today announced top-line results from the pooled cardiovascular (CV) safety analyses of the global Phase III programme for roxadustat, a first-in-class hypoxia-